MicroRNAs | Key effects |
miR-124 | Stimulates neuronal differentiation, reduces neuroinflammation, promotes recovery after stroke and spinal cord injury. |
miR-133b | One of the best-known regulators of axon growth and neuroplasticity; it enhances recovery after stroke. |
miR-21 | Protects neurons from apoptosis, reduces inflammation, and promotes axon regeneration. |
miR-17-92 (кластер) | Enhances neurogenesis, axon growth, and functional recovery. |
miR-26a | Stimulates peripheral nerve regeneration and axon growth. |
miR-146a | It suppresses microglial inflammatory responses and promotes neuroprotection. |
miR-132 | It participates in synapse formation, dendrite growth, and neuroplasticity. |
miR-9 | It regulates neuronal development and the formation of new nerve cells. |
miR-219 | One of the key regulators of oligodendrocyte maturation and remyelination. |
miR-338 | Promotes the restoration of myelin and oligodendrocyte function. |
miR-210 | Enhances angiogenesis and improves the recovery of brain tissue following ischemia. |
miR-181c | It may reduce post-stroke damage through an anti-inflammatory effect (the role depends on the context). |
miR-29b | Reduces fibrosis and supports neuronal survival and tissue repair. |
miR-30d | It exhibits a neuroprotective effect and reduces apoptosis. |
miR-125b | It participates in neuronal maturation; however, its overexpression can have adverse effects, so its action depends on the level and conditions. |
GROWTH FACTORS | The primary task regarding the skin |
EGF | proliferation and migration of keratinocytes, epithelization |
FGF-2 (bFGF) | fibroblast activation, dermal regeneration |
KGF / FGF-7 | epidermal regeneration, keratinocytes |
PDGF-AA/BB | fibroblasts, ECM remodeling, healing |
IGF-1 | cell survival, matrix synthesis, regeneration |
HGF | regeneration, cell migration, anti-inflammatory effect |
VEGF-A | angiogenesis and microcirculation |
TGF-β3 | ECM remodeling and repair |
TGF-β1 | collagen synthesis |
miRNA | Interest |
miR-29b-3p | Photoaging, ECM, collagen remodeling |
miR-29a-3p | ECM and fibrosis |
miR-146a-5p | Inflammation, cellular senescence, collagen homeostasis |
miR-126-3p | Angiogenesis and microcirculation |
miR-126-5p | Endothelial function |
miR-21-5p | Repair, cell migration |
miR-1246 | UVB/photoaging, collagen, anti-inflammatory activity |
miR-125b-5p | Aging/differentiation |
miR-130a/b | Angiogenesis and repair |
miR-135a | ECM/fibroblast regulation |
miR-181a | Inflammation and Aging |
miR-210-3p | Hypoxia, angiogenesis, regeneration |
miR-27a/b | Repair/angiogenic pathways |
miR-31-5p | Migration and proliferation of keratinocytes |
miR-221/222 | Proliferation and vascular signaling |
Component | Main action |
Perforin | Formation of pores in the target cell membrane |
Granzyme B | Triggering apoptosis |
Granzyme A | Cytotoxic effect |
Granulysin | Cytolytic/antimicrobial activity |
FasL (CD95L) | Activation of Fas-dependent apoptosis |
TRAIL | Induction of apoptosis in tumor cells |
miRNA | Regulation of gene expression in a target cell |
CD56 | Characteristic NK-associated marker |
CD63, CD81, CD9 | Typical EV/exosomal markers |
NK-EX-1 | NK-EX-5 | NK-EX-10 | |
Vial volume | 10 ml | 10 ml | 10 ml |
Number of exosomes in the vial | 12 billions | 60 billions | 120 billions |
Indication | Cancer prevention | Treatment of infections | Cancer treatment |
Frequency of use | 1 vial 1–3 times a year | 1 vial once a week | 1 vial 1–2 times a week |
Course of treatment | 1-2 weeks | 2-4 weeks |
Parameter | NK-cells | NK-EX |
Direct destruction of the target cell | Very strong | Strong |
Perforin, granzymes | +++ | ++ |
FasL / TRAIL | +++ | +/++ |
Cell viability is required | Yes | No |
Dependence on the immunosuppressive tumor microenvironment | High | Low |
Penetration into the dense tissue of a tumor | Limited | High |
Storage and standardization | Difficult, 24 hours, instability | Simple, 2 years, stability |
The risk of uncontrolled behavior in living cells | Yes | No |
There are three main methods for producing exosomes:
We use our own ultrafiltration method.
During the MMSC cultivation process, exosomes are isolated into a nutrient medium. After MMSC isolation, a solution containing exosomes (supernatant) remains in the cultivation chamber.
The supernatant is then filtered and concentrated (5 or 10 times), and packaged.
DOKAR Laboratory has developed its own exosome production technology—triple filtration and concentration.
We use 0.22 and 0.45 µm filters and dialysis cartridges.
We have created our own exosome concentration system.
DC-EX ORDER
To order DC-EX exosomal products, please text us to email: dokartest@gmail.com